Johnson & Johnson (JNJ) ended Friday at $232.77, gaining 2.02%, while the broader market experienced a significant sell-off. The SPDR S&P 500 ETF Trust (SPY) fell 2.61%, and the Nasdaq Composite slid 4.2%, driven by rate fears pressuring growth stocks. J&J's performance stood out as investors rotated into healthcare and other defensive sectors.
Defensive Rotation Boosts Healthcare
The healthcare sector broadly outperformed, with the Health Care Select Sector SPDR ETF (XLV) adding 0.61%. Other major pharmaceutical stocks also gained, including Pfizer (PFE) and Merck (MRK), which rose 1.4% and 0.5%, respectively. However, J&J's 2.0% gain was notably stronger, suggesting company-specific factors beyond the sector rotation.
Legal Victory and Ongoing Risks
On Friday, a Los Angeles jury found Johnson & Johnson not negligent in a lawsuit brought by families of three women who claimed its talc products caused ovarian cancer. This verdict provides a temporary reprieve, but the company still faces over 67,000 talc-related lawsuits, with mixed outcomes in previous cases. The ongoing litigation remains a significant overhang for the stock.
Pipeline and Product Transition
J&J is navigating the patent expiration of its blockbuster drug Stelara, which saw first-quarter sales decline approximately 60% due to biosimilar competition. The company is betting on new products to offset this decline. CEO Joaquin Duato highlighted a "strong start to 2026," citing recent approvals for Icotyde in plaque psoriasis and Varipulse Pro in Europe. CFO Joseph Wolk noted that patients are transitioning to Tremfya, and Jennifer Taubert described Icotyde's launch as "very fast," with potential to become one of J&J's largest products.
Positive Pipeline Data
Pipeline developments were in focus last week. On June 3, J&J announced that its drug nipocalimab met its primary endpoint in a Phase 2 lupus trial. New Phase 2 data in Sjögren's disease also showed higher response rates in patients with elevated autoantibody and IgG levels, who typically experience more severe symptoms.
Upcoming Catalysts
Investors are looking ahead to next week, when J&J management is scheduled to speak at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 10:00 a.m. Eastern. The fireside chat is expected to provide updates on drug launches, MedTech trends, and the company's outlook on litigation. Additionally, J&J will pay its next quarterly dividend of $1.34 per share on June 9 to shareholders of record as of May 26. The company raised its dividend by 3.1% in April, marking its 64th consecutive annual increase.
Financial Performance
J&J reported first-quarter sales of $24.1 billion, a 9.9% increase, with adjusted EPS of $2.70. The company raised its 2026 guidance, forecasting reported sales of $100.8 billion at the midpoint and adjusted earnings of $11.55 per share. While the dividend streak provides support, the stock remains vulnerable to earnings disappointments or adverse trial outcomes.
